Notch activation complex kinase (NACK)

Notch activation complex kinase (NACK) is a pivotal co-activator within the Notch signaling pathway, essential for the transcriptional activation of Notch target genes (Weaver et al., 2014, Nature Communications). It functions by associating with the Notch intracellular domain (NICD) and the Mastermind-like (MAML) protein to form a transcriptionally active complex on DNA, facilitating the recruitment of RNA polymerase II (Wang et al., 2018, Blood). NACK is frequently overexpressed in various malignancies, most notably T-cell acute lymphoblastic leukemia (T-ALL) and esophageal adenocarcinoma, where it promotes oncogenic signaling and tumor cell proliferation (Weaver et al., 2014). Because NACK acts downstream of the proteolytic cleavage of the Notch receptor, it represents a specialized therapeutic target that may bypass some of the limitations and resistance mechanisms associated with gamma-secretase inhibitors (Astudillo et al., 2016, Expert Opinion on Therapeutic Targets). Experimental small molecule inhibitors targeting NACK, such as NACKi-1, have demonstrated the ability to disrupt the Notch transcriptional complex, leading to decreased expression of oncogenes like MYC and inducing growth arrest in cancer cells (Wang et al., 2018). Consequently, NACK is being investigated as a high-priority target for precision oncology in Notch-dependent tumors, offering a potentially more selective approach than pan-Notch inhibition.

Other names

BCL2L12Bcl-2-like protein 12Notch-dependent kinaseNACK kinase

Inhibition of the Notch transcriptional activation complex by disrupting the recruitment of NACK to the Notch intracellular domain (NICD) and Mastermind-like (MAML) complex, thereby preventing the transcription of oncogenic Notch target genes.